Abstract: The present disclosure provides a DC concentrated illumination system, including a DC distribution box configured for converting a command specification that controls the state of lamps into a voltage signal with a varying amplitude, and outputting the voltage signal via a power line; and a plurality of lamp units, each includes a lamp, a power conversion unit and a simulated load unit, wherein the power conversion unit is coupled to the lamp and the simulated load unit, and is coupled to the DC distribution box via the power line. The power conversion unit receives the voltage signal and collects the state information of the lamps when the voltage signal matches a preset convention rule successfully; and the power conversion unit controls the action of the simulated load unit to get a current signal, the DC distribution box parses the current signal to obtain the state information of the lamps.

Abstract: Porous silicon (pSi) microparticles (PSM) are disclosed, which provide an important advance in the area of cancer immunotherapeutics and molecular nanomedicine. In particular, potent PSM-based adjuvants are disclosed for dendritic cell-based vaccines compositions, and methods for their use in a variety of cancer immunotherapies. The PSM of the present invention are also useful in developing other types of vaccines, including those not necessarily related to the treatment of cancers, such as vaccines for the treatment of acne, Alzheimer's disease, asthma, atherosclerosis, autoimmune disorders, autoinflammatory disease, celiac disease, colitis, Crohn's disease, diabetes, glomerulonephritis, infectious diseases, inflammatory bowel disease, irritable bowel syndrome, ischemia, Lupus, pelvic inflammatory disease, reperfusion injury, rheumatoid arthritis, sarcoidosis, transplant rejection, West Nile virus, and related illnesses.

Abstract: Disclosed are mesoporous silicon multi-stage vehicles that comprise liposomal-based second-stage particles, as well as pharmaceutical compositions and formulations including such vectors for use in a variety of diagnostic and therapeutic indications. In particular embodiments, MSV comprising ligand decorated second-stage particles are provided for therapeutic methods including, for example, treatment of mammalian cancers, including those of the human breast.